Table 1 Patient disease and transplant characteristics according to donor type
Characteristics | Total N = 1239 | MSD N = 215 | MUD N = 235 | Haplo N = 789 | p |
|---|---|---|---|---|---|
Age in years, median (range) | 52 (18–75) | 48 (18–71) | 47 (18–74) | 54 (18–75) | < 0.001 |
Gender, n (%) | Â | Â | Â | Â | 0.9 |
 Male | 693 (56) | 117 (54) | 132 (56) | 444 (56) |  |
 Female | 546 (44) | 98 (46) | 103 (44) | 345 (44) |  |
Karnofsky performance status, n (%) | Â | Â | Â | Â | 0.2 |
 ≥ 90 | 929 (79) | 159 (77) | 192 (83) | 578 (78) |  |
 < 90 | 251 (21) | 48 (23) | 39 (17) | 164 (22) |  |
 Missing | 59 | 8 | 4 | 47 |  |
Cytogenetic risk category, n (%) | Â | Â | Â | Â | 0.2 |
 Standard | 47 (6) | 10 (8) | 8 (6) | 29 (5) |  |
 Intermediate | 543 (66) | 92 (70) | 87 (60) | 364 (66) |  |
 High | 239 (29) | 29 (22) | 49 (34) | 161 (29) |  |
 Missing | 410 | 84 | 91 | 235 |  |
Type of AML, n (%) |  |  |  |  | < 0.001 |
 De novo | 1046 (84) | 188 (87) | 216 (92) | 642 (81) |  |
 Secondary | 193 (16) | 27 (13) | 19 (8) | 147 (19) |  |
Months from diagnosis to transplant, median (range) | 5 (1-18) | 4 (1-18) | 5 (2-18) | 5 (1-18) | < 0.001 |
Conditioning intensity, n (%) | Â | Â | Â | Â | 0.03 |
 Myeloablative | 725 (59) | 122 (58) | 116 (50) | 487 (62) |  |
 Reduced intensity | 500 (41) | 87 (42) | 115 (50) | 298 (38) |  |
 Missing | 14 | 6 | 4 | 4 |  |
Type of conditioning, n (%) | Â | Â | Â | Â | 0.2 |
 Based on chemotherapy | 950 (77) | 159 (75) | 172 (75) | 619 (78) |  |
 Based on TBI | 287 (23) | 54 (25) | 63 (25) | 170 (22) |  |
 Missing | 2 | 2 | 0 | 0 |  |
Stem cell source, n (%) |  |  |  |  | < 0.001 |
 Bone marrow | 425 (34) | 62 (29) | 22 (9) | 341 (43) |  |
 Mobilized peripheral blood | 814 (66) | 152 (71) | 213 (91) | 448 (57) |  |
In vivo T cell depletion, n (%) | 164 (13) | 29 (13) | 63 (27) | 72 (9) | < 0.001 |
GvHD prophylaxis, n (%) |  |  |  |  | < 0.001 |
 PTCy + 2 drugs | 897 (72) | 56 (26) | 111 (47) | 730 (93) |  |
 PTCy + 1 drug | 265 (21) | 108 (50) | 111 (47) | 46 (6) |  |
 PTCy only | 77 (6) | 51 (24) | 13 (6) | 13 (2) |  |
Donor-recipient gender combination, n (%) | Â | Â | Â | Â | 0.02 |
 Female donor to male recipient | 249 (20) | 54 (25) | 34 (14) | 161 (20) |  |
 Other combinations | 988 (80) | 161 (75) | 201 (86) | 626 (80) |  |
 Missing | 2 | 0 | 0 | 2 |  |
Donor-recipient CMV serostatus, n (%) |  |  |  |  | < 0.001 |
 Negative-negative | 181 (15) | 33 (16) | 49 (21) | 99 (13) |  |
 Positive-negative | 82 (7) | 13 (6) | 13 (6) | 56 (7) |  |
 Negative-positive | 248 (21) | 17 (13) | 73 (32) | 148 (19) |  |
 Positive-positive | 680 (57) | 129 (64) | 94 (41) | 457 (60) |  |
 Missing | 48 | 13 | 6 | 29 |  |